Nchi: Armenia
Lugha: Kiingereza
Chanzo: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում
magnesium aspartate (magnesium aspartate tetrahydrate), potassium aspartate (potassium aspartate hemihydrate)
Gedeon Richter PLC
A12CC30
magnesium aspartate (magnesium aspartate tetrahydrate), potassium aspartate (potassium aspartate hemihydrate)
140mg+ 158mg
tablets film-coated
(50) in plastic container
OTC
Registered
2016-02-04
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Panangin ® 158 mg/140 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 158 mg potassium aspartate anhydride (in the form of 166.3 mg potassium aspartate hemihydrate) and 140 mg magnesium aspartate anhydride (in the form of 175 mg magnesium aspartate tetrahydrate). For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Film-coated tablet. White or almost white coloured, slightly polished, almost odourless, biconvex, round, film-coated tablets with a slightly uneven surface. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS As a supplement for treatment of potassium and magnesium deficiency. According to the approval of the attending physician: - as a part of combination therapy of chronic heart disease (heart failure in post-infarction patients), cardiac arrhythmia (ventricular, primarily). - add-on to cardiac glycoside therapy. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology _Adults_ The usual dose is 1 to 2 film-coated tablets three times daily. The daily dose may be increased to 3 times 3 film-coated tablets. _Paediatric population_ Children and adolescents The safety and efficacy of Panangin film-coated tablets in children and adolescents have not been established. No data are available. Method of administration For oral administration. Gastric acid may reduce the effectiveness of this preparation and therefore, it is recommended to take Panangin after meals. 4.3 CONTRAINDICATIONS Hypersensitivity to the active substances or to any of the excipients listed in section 6.1. 2 Acute or chronic renal failure. Addison’s disease. Grade III atrioventricular block. Cardiogenic shock (BP <90 mmHg). Children's age under 18 years. 4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE Particular caution is necessary in patients suffering from disorders associated with hyperkalaemia. Regular monitoring of serum electrolytes is recommended. This medicine contains 36.2 mg potassium in each f Soma hati kamili